Most Viewed: Last ONE YEAR
  • Review|Open Access

    Radiological diagnosis of hepatocellular carcinoma in non-cirrhotic patients

    Alba Castán , Ylenia Navarro , Luis Sarría , Raquel Larrosa , Mario Serradilla , Alejandro Serrablo
    Hepatocellular carcinoma (HCC) arising in non-cirrhotic livers is relatively rare. Compared with HCC arising in cirrhotic livers they have some quirks. HCC in healthy livers are large tumors at diagnosis, and are detected due to the onset of abdominal symptoms, outside of any scheduled monitoring program. In non-cirrhotic patients, HCC has the same appearance as the classic image of cirrhotic HCC substrate. The presence of capsule, extensive intratumoral necrosis and typical behavior in the dynamic study after administration of intravenous contrast are present in most of the non-cirrhotic... Read more
    Hepatoma Res 2017;3:1-17. | doi:10.20517/2394-5079.2015.62
    Published on: 12 Jan 2017  | Viewed:5451  | Downloaded:260
    +HTML| PDF
  • Minireview|Open Access

    Updates on hepatorenal syndrome and strategies bridging to liver transplantation

    Chung Yeung Cheung , Kenneth S.H. Chok
    Hepatorenal syndrome is not an uncommon life-threatening complication arising from liver cirrhosis. The diagnostic criteria for this syndrome have been revised throughout the years, with recent revisions aimed at improving earlier diagnosis and treatment. Liver transplantation remains the only definitive treatment for hepatorenal syndrome. Due to the scarcity of liver grafts, many patients die waiting. This review focuses on the different strategies to bridge patients to liver transplantation and to improve the postoperative outcome. Read more
    Hepatoma Res 2017;3:67-72. | doi:10.20517/2394-5079.2016.48
    Published on: 12 Apr 2017  | Viewed:3767  | Downloaded:380
    +HTML| PDF
  • Review|Open Access

    Management of advanced hepatocellular carcinoma: review of current and potential therapies

    Asmaa Gomaa , Imam Waked
    Over the past few years, despite improvement in screening and diagnosis of hepatocellular carcinoma (HCC), advanced stage remains the most common presentation at diagnosis, with limited management options, especially options available to patients in limited resource countries. There is currently no effective systemic chemotherapy, targeted, or immunologic therapy for advanced stage HCC. Sorafenib is the only approved front-line molecular-targeted treatment,with slight survival benefit. Regorafenib has recently been approved as second line therapy for HCC after failure of sorafenib. Ongoing... Read more
    Hepatoma Res 2017;3:112-22. | doi:10.20517/2394-5079.2017.03
    Published on: 15 Jun 2017  | Viewed:3231  | Downloaded:457
    +HTML| PDF
  • Topic: Advances in the diagnosis and treatment of liver fibrosis|Open Access

    Advances in the diagnosis and treatment of liver fibrosis

    Jenny Yeuk-Ki Cheng , Grace Lai-Hung Wong
    Liver fibrosis is the center of diagnosis and management of essentially all chronic liver diseases. While liver biopsy examination still has a role in diagnosis and drug development, it is replaced by non-invasive assessments of liver biopsy in majority of the clinical scenarios. Radiological approaches, namely transient elastography, acoustic radiation force impulse imaging, shear wave elastography, magnetic resonance elastography provide accurate diagnosis of advanced fibrosis and cirrhosis. Serum test formulae based on common laboratory parameters or more specialized parameters including... Read more
    Hepatoma Res 2017;3:156-69. | doi:10.20517/2394-5079.2017.27
    Published on: 8 Aug 2017  | Viewed:2909  | Downloaded:189
    +HTML| PDF
  • Original Article|Open Access

    In vitro antitumor efficacy of Kochia indica extract on human hepatocellular carcinoma cell line with or without 5-fluorouracil

    Nabil Mohie Abdel-Hamid , Ghada A. Tabl , Yousry E. El-Bolkiny , Walaa O. Zeina
    Aim: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the sixth most common cancer worldwide. The resistance to chemotherapy is a major obstacle in the treatment of HCC, necessitating the discovery of additional agents. There is a growing use of anticancer complementary and alternative medicine worldwide. Therefore, the aim of present study was focused on the confirmation of the suitability and validity of the new markers which would be achieved by demonstrating their significant change and reproducible expression during disease and disease management. Methods:... Read more
    Hepatoma Res 2017;3:149-55. | doi:10.20517/2394-5079.2016.50
    Published on: 21 Jul 2017  | Viewed:2317  | Downloaded:53
    +HTML| PDF
  • Topic: Novel Approaches for HCC|Open Access

    Immunotherapy for hepatocellular carcinoma: the force awakens in HCC?

    Lynn G. Feun , Ying-Ying Li , Medhi Wangpaichitr , Chun-Jing Wu , Niramol Savaraj
    Systemic therapy for hepatocellular carcinoma (HCC) has been disappointing. The only drug approved by Food and Drug Administration recently has been sorafenib. Sorafenib has modest benefits with a low response rate and an improvement in time to progression of only 2-3 months. Multiple randomized trials, which compare the new agent to sorafenib as either first line or second line therapy, have been negative, showing no improved clinical benefit. Recently, in a large phase III randomized trial, regorafenib has shown superiority to placebo as a second line treatment for HCC. However, this drug... Read more
    Hepatoma Res 2017;3:43-51. | doi:10.20517/2394-5079.2016.45
    Published on: 22 Mar 2017  | Viewed:2308  | Downloaded:669
    +HTML| PDF
  • Review|Open Access

    Novel predictive and prognostic strategies of hepatitis B virus related hepatocellular carcinoma

    Wen-Bin Liu , Fan Yang , Ding-Yi Shao , Guang-Wen Cao
    Hepatocellular carcinoma (HCC) is a common malignancy and an important cause of cancer death worldwide. Chronic hepatitis B virus (HBV) infection is the major cause of HCC. Recent studies of HBV-induced carcinogenesis not only discovered many new biomarkers but also developed a novel theory: Cancer Evolution-Development (Cancer Evo-Dev). Cancer Evo-Dev provides an evolutionary insight of developing more reasonable predictive and prognostic strategies. Characterizing chronic inflammatory microenvironment of cancer evolution, genetic polymorphisms of inflammatory factors, and HCC-related HBV... Read more
    Hepatoma Res 2016;2:331-40. | doi:10.20517/2394-5079.2016.38
    Published on: 23 Dec 2016  | Viewed:2262  | Downloaded:126
    +HTML| PDF
  • Original Article|Open Access

    Late recurrence of hepatocellular carcinoma after liver transplantation

    Julia A. Zhang , Sandi A. Kwee , Linda L. Wong
    Aim: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and liver transplant (LT) prolongs survival. However, 15-20% will experience recurrent HCC, most occurring within 2 years of LT. HCC patients with late recurrences (> 5 years after LT) may have distinctive clinical/biological characteristics. Methods: A retrospective review was conducted of 88 patients who underwent LT for HCC during 1993-2015, analyzing demographics, clinical factors, explant pathology, and outcome. Results: Median follow-up was 6.4 years. HCC recurred in 15 (17.0%) patients with... Read more
    Hepatoma Res 2017;3:58-66. | doi:10.20517/2394-5079.2017.05
    Published on: 10 Apr 2017  | Viewed:1414  | Downloaded:112
    +HTML| PDF
  • Original Article|Open Access

    Antioxidant activity and free radical-scavenging of cape gooseberry (Physalis peruviana L.) in hepatocellular carcinoma rats model

    Hanaa A. Hassan , Nermin E. Ghareb , Ghassan F. Azhari
    Aim: Oxidative damage of cellular components by free radicals and other reactive oxygen molecules is believed to be associated with the development of degenerative diseases. The aim of the present study was to evaluate the antioxidant capacity and free radical scavenging activity of cape gooseberry juice (CGJ) in diethylnitrosamine-(DENA) and CCl4 (3 mL/kg b.w.)-induced hepatocellular carcinoma (HCC) rats model. Methods: The rats were divided into 4 groups (6 rats each group). Group 1 (control): the rats of this group did not receive any treatments; group 2 (CGJ): rats were daily... Read more
    Hepatoma Res 2017;3:27-33. | doi:10.20517/2394-5079.2016.33
    Published on: 28 Feb 2017  | Viewed:1383  | Downloaded:119
    +HTML| PDF
  • Editorial|Open Access

    Liver transplantation in acute-on-chronic liver failure

    Roger Williams
    Hepatoma Res 2017;3:90-4. | doi:10.20517/2394-5079.2017.13
    Published on: 17 May 2017  | Viewed:1361  | Downloaded:101
    +HTML| PDF
  • Original Article|Open Access

    Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma

    Hie-Won Hann , Surbhi Jain , Grace Park , Jamin D. Steffen , Wei Song , Ying-Hsiu Su
    Aim: This study aimed to explore the potential of detecting hepatocellular carcinoma (HCC)-associated DNA markers, TP53 249T mutations and aberrant methylation of RASSF1A and GSTP1 genes, for monitoring HCC recurrence. HCC remains a leading cause of death worldwide, with one of the fastest growing incidence rates in the US. While treatment options are available and new ones emerging, there remains a poor prognosis of this disease mostly due to its late diagnosis and high recurrence rate. Although there are no specific guidelines addressing how HCC recurrence should be monitored, recurrence... Read more
    Hepatoma Res 2017;3:105-11. | doi:10.20517/2394-5079.2017.15
    Published on: 6 Jun 2017  | Viewed:1270  | Downloaded:161
    +HTML| PDF
  • Viewpoint of Editor-in-Chief|Open Access

    Cancer Evo-Dev, a novel hypothesis derived from studies on hepatitis B virus-induced carcinogenesis

    Guang-Wen Cao
    Non-resolving inflammation, which may be maintained by infection, pollution, and metabolic stimulants and their interactions with immunogenetic predisposition, provides a fertile field for cancer development. This is strongly evident in hepatocellular carcinoma. Here, the framework of a hypothesis called Cancer Evo-Dev is presented, based on the advances in hepatitis B virus-induced hepatocarcinogenesis. Several aspects central to this theory are as follows: (1) immune imbalance caused by the interaction of immunogenetic predispositions and hepatitis B virus infection maintains... Read more
    Hepatoma Res 2017;3:241-59. | doi:10.20517/2394-5079.2017.45
    Published on: 27 Oct 2017  | Viewed:1171  | Downloaded:75
    +HTML| PDF
  • Original Article|Open Access

    Use of gadobenate dimeglumine dynamic MRI for detection of early hepatocellular carcinoma in atypical hepatic focal lesions

    Mohamed F. El-Gazzar , Mohamed Ahmed Samy Kohla , Mahmoud M. El-Sakhawy , Mohamed M. Husseiny , Reda R. H. Yousef , Safinaz H. El-Shorbagy
    Aim: Gadobenate dimeglumine (multihance) is a contrast medium which can be used not only as an extracellular contrast agent for dynamic imaging of the liver, but also as a liver specific agent for the acquisition of hepatobiliary-phase images which are more helpful in evaluation of small atypical hepatic focal lesions equal or less than 3 cm. The authors tried to evaluate multihance dynamic magnetic resonance imaging (MRI) as a new modality in early detection of hepatocellular carcinoma (HCC). Methods: Thirty cirrhotic patients with small hepatic focal lesions (less than 3 cm in diameter),... Read more
    Hepatoma Res 2017;3:123-8. | doi:10.20517/2394-5079.2017.08
    Published on: 26 Jun 2017  | Viewed:1134  | Downloaded:85
    +HTML| PDF
  • Original Article|Open Access

    Comparison of p53 and prohibitin expression in the spectrum of hepatitis, cirrhosis, and hepatocellular carcinoma

    Lívia Maria Della Porta , Fernando Silva Ramalho , Carlos Augusto Oliveira , Deisy Mara Silva , Marlei Josiele Augusto , Leandra Náira Zambelli Ramalho
    Aim: To investigate the correlation of p53 and prohibitin (PHB) expression in the spectrum of hepatitis, cirrhosis, and human hepatocellular carcinoma (HCC). Methods: Hepatic biopsies from patients with HCC (n = 60), cirrhosis (CIR, n = 30), hepatitis C virus (HCV, n = 30), and normal livers (NL, n = 20) were examined for immunohistochemical expression of RelA/p65, tumor necrosis factor receptor-1 (TNFR1), TNF-related apoptosis-inducing ligand (TRAIL), p53, and PHB. The samples were also analysed by nuclear factor kappa B (NFκB) Southwestern histochemistry and a transferase-mediated... Read more
    Hepatoma Res 2017;3:34-42. | doi:10.20517/2394-5079.2016.39
    Published on: 28 Feb 2017  | Viewed:1094  | Downloaded:65
    +HTML| PDF
  • Case Report|Open Access

    Hepatocellular carcinoma following direct anti-viral for hepatitis C treatment: a report of an Egyptian case series

    Eman A. Rewisha , Maha M. Elsabaawy , Omar Elshaarawy , Ayat Abdullah , Dalia M. Elsabaawy , Omkolsoum M. Alhaddad
    Egypt had been vexed by the highest load of chronic hepatitis C in the world. It represents a vast market of the new direct-acting anti-viral drugs (DAAs); effectively treating chronic hepatitis C virus (HCV) infection. Eradication of HCV in Egypt has been challenged by the observed increased diagnosis of hepatocellular carcinoma (HCC) in relation to DAAs therapy. This is the first Egyptian report annotating to a series of sixteen chronic HCV infected cases without a diagnosis of HCC before DAAs therapy and unexpected development of HCC during or after completion of DAAs therapy. Read more
    Hepatoma Res 2017;3:178-81. | doi:10.20517/2394-5079.2017.18
    Published on: 11 Aug 2017  | Viewed:1087  | Downloaded:140
    +HTML| PDF
  • Original Article|Open Access

    MELD score and AST-to-platelet ratio index predict long-term survival in patients with a small hepatocellular carcinoma following non-transplant therapies: a pilot study

    Joy Sarkar , Thomas DeLeon , Linda L. Wong
    Aim: Liver transplantation (LT) is the most effective treatment for long-term survival from hepatocellular carcinoma (HCC); however, insufficient donors limit therapy. The authors sought to identify characteristics that predicted long-term survival after non-transplant therapies in patients with small HCC. Methods: In a database of 1,050 HCC patients, the authors identified those with single HCC ≤ 3.0 cm, who underwent hepatic resection (HR, n = 16), radiofrequency ablation (RFA, n = 55), or LT (n = 23) with 5-year follow-up. Overall survival (OS) and odds-ratios (OR) for survival after... Read more
    Hepatoma Res 2017;3:79-85. | doi:10.20517/2394-5079.2017.06
    Published on: 9 May 2017  | Viewed:1048  | Downloaded:69
    +HTML| PDF
  • Review|Open Access

    Roles of p53 in extrinsic factor-induced liver carcinogenesis

    Tim Link , Tomoo Iwakuma
    Liver cancer remains one of the most common human cancers with a high mortality rate. Therapies for hepatocellular carcinoma (HCC) remain ineffective, due to the heterogeneity of HCC with regard to both the etiology and mutation spectrum, as well as its chemotherapy resistant nature; thus surgical resection and liver transplantation remain the gold standard of patient care. The most common etiologies of HCC are extrinsic factors. Humans have multiple defense mechanisms against extrinsic factor-induced carcinogenesis, of which tumor suppressors play crucial roles in preventing normal cells... Read more
    Hepatoma Res 2017;3:95-104. | doi:10.20517/2394-5079.2017.07
    Published on: 6 Jun 2017  | Viewed:1011  | Downloaded:66
    +HTML| PDF
  • Review|Open Access

    Reducing liver cancer risk beginning at birth: experiences of preventing chronic hepatitis B virus infection in China

    Chunfeng Qu , Zhongping Duan , Kun Chen , Huaibin Zou
    In China, the death numbers due to primary liver cancer every year account for more than half of this disease burden worldwide. Hepatocellular carcinoma (HCC) represents the major histological type of primary liver cancer. In the Chinese population, at least 85% HCC cases are due to chronic infection with hepatitis B virus (HBV), most of which were acquired in the perinatal period or in early life. As of January 1992, HBV immunization of newborns was introduced to the national Expended Program of Immunization of China. Prior to this program, the Qidong County in China conducted an hepatitis... Read more
    Hepatoma Res 2017;3:228-40. | doi:10.20517/2394-5079.2017.41
    Published on: 25 Oct 2017  | Viewed:960  | Downloaded:43
    +HTML| PDF
  • Case Report|Open Access

    Sorafenib from palliative to neoadjuvant chemotherapy in hepatocellular carcinoma with major vascular invasion: experience of two cases

    Naganathan Selvakumar , Sandeep Vohra , Deep Sika Arora , Subash Gupta
    Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the incidence is higher in cirrhosis. Treatment options depend on tumor stage, status of liver function, and the general condition of the patient. Major vascular invasion is a contraindication for liver transplantation. Sorafenib has been found to be useful in association with transarterial chemoembolization as an effective chemotherapeutic agent to prolong survival in inoperable HCCs. Here we describe our experience where sorafenib was used as palliation but later turned out to be a neoadjuvant. Both cases had... Read more
    Hepatoma Res 2017;3:18-21. | doi:10.20517/2394-5079.2016.14
    Published on: 12 Jan 2017  | Viewed:913  | Downloaded:76
    +HTML| PDF
  • Review|Open Access

    Further understanding of mechanisms involved in liver cancer chemoresistance

    Oscar Briz , Maria J. Perez , Jose J. G. Marin
    An important limitation for the success of chemotherapy in the treatment of primary liver cancer (hepatocellular carcinoma, hepatoblastoma and cholangiocarcinoma) is the marked efficacy of mechanisms of chemoresistance (MOC). These have been previously classified into five groups depending on whether they result in: a reduced drug uptake or enhanced drug export (MOC-1); poor intracellular activation of prodrugs or higher inactivation of active drugs (MOC-2); changes in the molecular targets that impairs the action of the drug by increasing the activity of the metabolic route to be inhibited... Read more
    Hepatoma Res 2017;3:22-6. | doi:10.20517/2394-5079.2016.22
    Published on: 19 Jan 2017  | Viewed:911  | Downloaded:180
    +HTML| PDF
Hepatoma Research Print ISSN: 2394-5079; Online ISSN: 2454-2520
Quick Links
  • OAE Publishing Inc. (OAE) is an online open-access publisher specializing in the publication of biomedical peer-reviewed journals...

  • Contact us
  • Leave feedback
Partners
Copyright © 2017 OAE Publishing Inc. All Rights Reserved.